Interestingly, the combination of VMO-ECT2-Ex5 and Doxo treatment significantly decreased tumor growth (P = 0.0152; comparing VMO-ECT2 + Doxo with VMO-CTRL; Figure 7B). This evidence concerns the gene ECT2 and neoplasm.